Pinto and colleagues provide an overview of MRI/TRUS fusion-guided transperineal biopsy utilizing the UroNav platform.
The video above, as well as videos from Arvin George, MD, and Andre L. Abreu, MD, illustrate techniques for performing transperineal prostate biopsy. Commentary on the videos is provided by Amir H. Lebastchi, MD, clinical fellow in urologic oncology, Urologic Oncology Branch, National Cancer Institute, Bethesda, MD.
Pinto and colleagues provide an overview of MRI/TRUS fusion-guided transperineal biopsy utilizing the UroNav platform. The various components of the biopsy module include a stepper, biopsy grid, ultrasound probe, and endocavity balloon (for elevation of the prostate into the image field). The patient is positioned in dorsal lithotomy position with the electromagnetic field generator just above the pelvis. After the prostate is outlined and aligned with the patient MRI, the targeted lesion is delineated over the ultrasound image. The endocavity balloon is then inflated to appropriately position the prostate within the region of the biopsy grid. Several cores are taken from the targeted region to ensure sufficient sampling of the target. Following biopsy of the targeted lesion, the prostate is then systemically biopsied using an extended sextant systematic 12-core biopsy.
Amir H. Lebastchi, MD
Peter A. Pinto, MD
Lebastchi is a clinical fellow in urologic oncology, O’Connor is a medical student, and Pinto is an investigator and head of the Prostate Cancer Section, Urologic Oncology Branch, National Cancer Institute, Bethesda, MD.
'Y'tube Section Editor James M. Hotaling, MD, MS, is assistant professor of surgery (urology) at the Center for Reconstructive Urology and Men's Health, University of Utah, Salt Lake City.
Relugolix plus radiotherapy shows safety, efficacy in prostate cancer
March 14th 2024“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.
Relugolix now available in Canada for advanced prostate cancer
March 13th 2024"Now, physicians in Canada have a once-daily oral GnRH antagonist treatment option in their armamentarium that helps men with advanced prostate cancer by lowering testosterone levels without leading to testosterone flares,” said Fred Saad, MD, FRCS.
Agents show potential to bolster precision medicine in prostate cancer
March 12th 2024"[Now that] we have entered the era of precision and personalized medicine, well-designed clinical trials are needed to address selected focused questions regarding optimal therapy sequencing,” says Maha H.A. Hussain, MBChB.
Enrollment complete in phase 2 study of PT-112 in mCRPC
March 8th 2024"We are confident in PT-112's potential as an effective treatment for patients with mCRPC who have progressed on androgen receptor directed therapy, chemotherapy or radioligand therapy and who lack any effective immunotherapy," says Robert Fallon.
Relugolix plus radiotherapy shows safety, efficacy in prostate cancer
March 14th 2024“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.
Relugolix now available in Canada for advanced prostate cancer
March 13th 2024"Now, physicians in Canada have a once-daily oral GnRH antagonist treatment option in their armamentarium that helps men with advanced prostate cancer by lowering testosterone levels without leading to testosterone flares,” said Fred Saad, MD, FRCS.
Agents show potential to bolster precision medicine in prostate cancer
March 12th 2024"[Now that] we have entered the era of precision and personalized medicine, well-designed clinical trials are needed to address selected focused questions regarding optimal therapy sequencing,” says Maha H.A. Hussain, MBChB.
Enrollment complete in phase 2 study of PT-112 in mCRPC
March 8th 2024"We are confident in PT-112's potential as an effective treatment for patients with mCRPC who have progressed on androgen receptor directed therapy, chemotherapy or radioligand therapy and who lack any effective immunotherapy," says Robert Fallon.
2 Commerce Drive
Cranbury, NJ 08512